您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 8420 处方药 8047 非处方药 267 保健品/医疗用具 106

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:


QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 芬兰药房
产地国家: 芬兰
所属类别: 激素内分泌药物->肾上腺皮质激素及促肾上腺皮质激素类药物
处方药:处方药
包装规格: 32毫克 20片/盒
计价单位:
  点击放大  
生产厂家中文参考译名:
辉瑞
生产厂家英文名:
Pfizer
该药品相关信息网址1:
https://www.rxlist.com/medrol-drug.htm
原产地英文商品名:
Medrol 32mg 20tabs/box
原产地英文药品名:
Methylprednisolone
中文参考商品译名:
美卓乐 32毫克 20片/盒
中文参考药品译名:
甲泼尼龙
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
Endocrine Disorders
英文适应病症2:
Rheumatic Disorders
英文适应病症3:
Collagen Diseases
临床试验期:
完成
中文适应病症参考翻译1:
内分泌紊乱
中文适应病症参考翻译2:
风湿性疾病
中文适应病症参考翻译3:
胶原蛋白疾病
药品信息:

---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件(201961821132537.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文美卓乐处方资料(仅供参考)

【英文名称】Medrol

【适用证】

--- 1.内分泌紊乱:

原发性或继发性肾上腺皮质功能不全(氢化可的松或可的松是首选;合成类似物可在适用的情况下与盐皮质激素联合使用;在婴儿期使用盐皮质激素补充剂尤其重要)。

先天性肾上腺增生

非化脓性甲状腺炎

与癌症相关的高钙血症

--- 2.风湿性疾病:

作为短期给药的辅助治疗(让患者渡过急性发作或恶化):

类风湿性关节炎,包括幼年型类风湿性关节炎(部分病例可能需要低剂量维持治疗)

强直性脊柱炎

急性和亚急性滑囊炎

骨关节炎的滑膜炎

急性非特异性腱鞘炎

创伤后骨关节炎

银屑病关节炎

上髁炎

急性痛风性关节炎

--- 3.胶原蛋白疾病:

在选定病例的恶化或维持治疗期间:

系统性红斑狼疮

系统性皮肌炎(多发性肌炎)

急性风湿性心脏炎

【用法用量】

根据所治疗的具体疾病实体,MEDROL片剂的初始剂量可以从每天4mg至48mg甲基强的松龙变化。在较不严重的情况下,较低剂量通常就足够了,而在选定的患者中,可能需要较高的初始剂量。应保持或调整初始剂量,直至注意到令人满意的反应。如果在一段合理的时间内没有令人满意的临床反应,应停止使用MEDROL,并将患者转入其他适当的治疗。

应该强调,剂量要求是可变的,并且必须根据治疗期间的疾病和患者的反应进行个体化。在注意到有利的反应后,应通过以适当的时间间隔以小的减量降低初始药物剂量来确定适当的维持剂量,直到达到将维持足够的临床反应的最低剂量。应该记住,需要持续监测药物剂量。在可能需要调整剂量的情况中包括继发于疾病过程中的缓解或恶化的临床状态的变化,患者的个体药物反应性,以及患者暴露于与治疗中的疾病实体不直接相关的压力情况的影响;在后一种情况下,可能需要增加MEDROL的剂量一段时间,与患者的病情一致。如果长期治疗后停药,建议逐渐停药而不是突然停药。

多发性硬化症

在治疗多发性硬化症的急性加重期间,每日服用200毫克泼尼松龙一周,然后每隔一天服用80毫克,持续1个月已被证实是有效的(4毫克甲基强的松龙相当于5毫克泼尼松龙) 。

【禁忌】

全身性真菌感染和已知的对组分的超敏反应。

【INDICATIONS AND USAGE】

MEDROL Tablets are indicated in the following conditions:

---1. Endocrine Disorders:

Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance).

Congenital adrenal hyperplasia

Nonsuppurative thyroiditis

Hypercalcemia associated with cancer

---2. Rheumatic Disorders:

As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:

Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)

Ankylosing spondylitis

Acute and subacute bursitis

Synovitis of osteoarthritis

Acute nonspecific tenosynovitis

Post-traumatic osteoarthritis

Psoriatic arthritis

Epicondylitis

Acute gouty arthritis

---3. Collagen Diseases:

During an exacerbation or as maintenance therapy in selected cases of:

Systemic lupus erythematosus

Systemic dermatomyositis (polymyositis)

Acute rheumatic carditis

【DOSAGE AND ADMINISTRATION】

The initial dosage of MEDROL Tablets may vary from 4 mg to 48 mg of methylprednisolone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, MEDROL should be discontinued and the patient transferred to other appropriate therapy.

IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of MEDROL for a period of time consistent with the patient's condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.

Multiple Sclerosis

In treatment of acute exacerbations of multiple sclerosis daily doses of 200 mg of prednisolone for a week followed by 80 mg every other day for 1 month have been shown to be effective (4 mg of methylprednisolone is equivalent to 5 mg of prednisolone).

【CONTRAINDICATIONS】

Systemic fungal infections and known hypersensitivity to components.

---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件(201961821132537.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 2019-6-18
附件:
201961821132537.pdf    

 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com